Here are a few brief analogies for Silo Pharma:

• Eli Lilly for psychedelic mental and neurological health.
• Biogen for psychedelic brain disorders.

• Therapeutics for Depression: Developing novel treatments for depression by merging traditional therapeutics with psychedelic research.
• Therapeutics for Post-Traumatic Stress Disorder (PTSD): Researching and advancing new therapeutic approaches for individuals suffering from PTSD.
• Therapeutics for Alzheimer's: Focusing on the development of innovative treatments for Alzheimer's disease.
• Therapeutics for Parkinson's: Exploring and creating therapies designed to address Parkinson's disease.
• Therapeutics for Rare Neurological Disorders: Investigating and developing treatments for a range of other rare neurological conditions.

Silo Pharma, Inc. (SILO) is a developmental stage biopharmaceutical company. At this stage, the company is primarily focused on research and development of potential therapeutic treatments and does not have any products approved for sale on the market. Therefore, Silo Pharma, Inc. does not currently have major customers that it sells products or services to, whether to other companies or to individuals.

• University of Maryland
• The Regents of the University of California
• Columbia University

Eric Weisblum, Chief Executive Officer and President

Eric Weisblum is the founder and Chief Executive Officer of Silo Pharma Inc.. Prior to founding Silo Pharma, he was a private investor and advisor to several of his portfolio companies. Mr. Weisblum has experience in both in-licensing therapeutic assets and assisting in their development. He brings nearly 20 years of experience in structuring and trading financial instruments. He also founded Whalehaven Capital LP in 2003 and is currently a Managing Member at Jaws Capital Partners LLC. His former positions include Independent Director at Dominari Holdings, Inc. and Director at Earth Brand Holdings, Inc.. He has also served on the board of Aikido Pharma and was the president of Sableridge Capital.

Daniel Ryweck, Chief Financial Officer and Principal Accounting Officer

Daniel Ryweck is a Certified Public Accountant. He has served as Chief Financial Officer for Silo Pharma since the effective time of its merger. Previously, he was the chief compliance officer for Mill City Ventures III Ltd from October 2013 and interim chief financial officer of Sun BioPharma, Inc.. Mr. Ryweck also served as a director of Dala Petroleum Corp. and has worked as a self-employed accountant since January 2000.

Dr. James Kuo, M.D., MBA, Vice President of R&D

Dr. James Kuo currently serves as Managing Director of Athena Bioventures. He is an experienced biotech industry executive and investor with a background in financial and management roles within private and listed bioscience companies across the U.S., Canada, and Europe. He is currently the Chairman of the Board of ImmunoPrecise Antibodies and a board director of Tryp Therapeutics. Dr. Kuo previously held CEO positions at Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, and Discovery Laboratories. Before that, he was an Associate Director in Corporate Licensing and Development at Pfizer and Managing Director of HealthCare Ventures, a $378 million venture fund.

Dr. Kevin Muñoz, Board Member

Dr. Kevin Muñoz was appointed to Silo Pharma's Board of Directors on October 1, 2020. He has recently been teaching Biomedical Sciences and medical intervention at the Passaic County Technical Institute. Dr. Muñoz previously served as Director of Operations at Physical Medicine and Rehabilitation.

Wayne Linsley, Board Member

Wayne Linsley has served as a director of Silo Pharma since January 2020. He brings over 40 years of experience in business management, encompassing sales and sales management, finance for both public and private companies, accounting, audit support, and financial reporting. From 2009 to September 2021, he worked for a financial reporting firm that specialized in publicly traded companies. Mr. Linsley possesses extensive knowledge of financial statements, MD&A, and SEC Filings.

1. Clinical Trial and Regulatory Failure Risk: As a developmental-stage biopharmaceutical company, Silo Pharma's success hinges entirely on its drug candidates successfully navigating lengthy, expensive, and uncertain clinical trials and subsequently receiving regulatory approval. The failure rate for drugs in clinical development is extremely high, with many candidates failing in early phases due to safety or efficacy issues. For psychedelic therapies, there are additional complexities including regulatory uncertainty regarding appropriate pathways, difficulties in designing placebo-controlled trials due to their brain-altering effects, and the need to carefully assess potential risks such as addiction, suicide potential, and adverse drug interactions. Silo Pharma's lead candidates are currently in preclinical stages, with Investigational New Drug (IND) applications and Phase 1 trials projected for 2025-2026, meaning no products are currently on the market or near commercialization. Delays in this process could significantly impede competitive positioning.
2. Financial Instability and Potential Delisting Risk: Developing new drugs is a capital-intensive endeavor, with costs estimated to be in the hundreds of millions to billions of dollars per product. Silo Pharma operates with a very low market capitalization and minimal revenue, making it highly dependent on securing substantial external funding. Furthermore, the company has received a notice of non-compliance from Nasdaq due to its stock price falling below the minimum bid requirement, with a deadline of June 22, 2026, to regain compliance or face potential delisting. This poses a significant and immediate threat to its public company status and ability to raise capital. The company's recent strategic move to establish a digital assets treasury, including purchases of volatile cryptocurrencies like Bitcoin and Ethereum, introduces additional financial risk.
3. Commercialization and Market Adoption Challenges for Psychedelic Therapies: Even if Silo Pharma's psychedelic-based therapies achieve regulatory approval, their commercialization faces unique challenges beyond traditional pharmaceuticals. These include difficulties in scaling treatment models, as psychedelic-assisted therapies often require trained professionals and supervised clinical settings, driving up costs and potentially limiting insurance coverage and patient access. There are also broader societal and ethical considerations regarding the commercialization of deeply personal psychedelic experiences, which could impact public acceptance and market penetration.

The aggressive entry and rapid acceleration of research and development by larger, well-established pharmaceutical companies into the nascent psychedelic therapeutics market pose a significant emerging threat to Silo Pharma. As the field gains scientific credibility and regulatory pathways become clearer, major pharmaceutical players with substantial financial resources, extensive R&D capabilities, and existing global distribution networks are increasingly likely to invest heavily in developing their own psychedelic-based treatments or acquiring more advanced pipelines. This could lead to a highly competitive landscape where Silo Pharma, as a developmental-stage company, struggles to compete for talent, secure funding, expedite clinical trials, or ultimately gain significant market share against incumbents with superior scale and infrastructure.

Silo Pharma Inc. focuses on developing therapeutics for several neurological and psychiatric disorders. The addressable markets for their main products or services, based on their areas of focus, are substantial globally and within the U.S.

• Post-Traumatic Stress Disorder (PTSD) and Stress-Induced Anxiety Disorders (Psychedelic Therapeutics): The global psychedelic therapeutics market, which includes treatments for depression, anxiety, and PTSD, was estimated at USD 2.94 billion in 2025 and is projected to grow to approximately USD 11.03 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 15.82% from 2025 to 2034. North America held approximately 52% of this market in 2024. More specifically for PTSD, the market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Australia) is expected to grow from USD 1.2 billion in 2024 to USD 5.5 billion by 2034, at a CAGR of 16.1%.
• Alzheimer's Disease: The global Alzheimer's therapeutics market was estimated at USD 6.49 billion in 2025 and is predicted to increase to approximately USD 33.62 billion by 2034, expanding at a CAGR of 20.06% from 2025 to 2034. North America dominated this market with 46.10% share in 2024. Another report indicates the global Alzheimer's drugs market size was valued at USD 21.07 billion in 2025 and is projected to reach USD 53.20 billion by 2034, registering a CAGR of 11.08%.
• Fibromyalgia and Chronic Pain: The global fibromyalgia treatment market was estimated at USD 2.3 billion in 2024 and is expected to grow to USD 3.4 billion by 2034, at a CAGR of 4.2% during the forecast period from 2025 to 2034. North America held the largest market share of 43.3% in 2024 for fibromyalgia treatment. Another estimate places the global fibromyalgia treatment market at USD 3.63 billion in 2025, projected to reach approximately USD 5.16 billion by 2034, growing at a CAGR of 3.97% from 2025 to 2034.
• Multiple Sclerosis (MS): The global multiple sclerosis therapeutic market size was estimated at USD 27.39 billion in 2024 and is projected to reach USD 38.62 billion by 2030, growing at a CAGR of 5.93% from 2025 to 2030. North America leads this market with a share of 38.28% in 2024. Another source indicates the global multiple sclerosis drugs market size was valued at USD 21.07 billion in 2025 and is projected to grow from USD 22.95 billion in 2026 to USD 53.20 billion by 2034, registering a CAGR of 11.08%.

Here are the expected drivers of future revenue growth for SILO Pharma (SILO) over the next 2-3 years:

1. Successful Clinical Development and Regulatory Approval of Lead Therapeutic Candidates: A primary driver of future revenue growth will be the successful advancement through clinical trials and eventual regulatory approval of its lead product candidates, specifically SPC-15 for Post-Traumatic Stress Disorder (PTSD) and SP-26 for fibromyalgia and chronic pain. SPC-15 is expected to file an Investigational New Drug (IND) application in 2025, with Phase 1 trials to follow, and has an exclusive global license from Columbia University. Similarly, SP-26 is on track to initiate IND-enabling studies in 2025, progressing toward Phase 1 trials. Both products are anticipated to launch by 2028, with revenue generation from their commercialization projected to begin around 2028 and contribute significantly by 2029. The potential for these candidates to qualify for the FDA's streamlined 505(b)(2) regulatory pathway could also accelerate their approval process.
2. Advancement of a Diversified Pipeline Targeting Significant Neurological and Metabolic Disorders: Beyond its lead assets, SILO Pharma's revenue growth will be driven by the progression of other pipeline candidates aimed at large and growing markets. This includes SPC-14 for Alzheimer's disease, for which an IND submission and Phase 1 trials are planned for 2025. The company is also developing SPU-16 for Multiple Sclerosis, with preclinical data readouts expected in 2025. Furthermore, a strategic 50:50 joint venture with Hoth Therapeutics Inc. to develop a treatment for obesity and metabolic diseases, targeting a $16 billion market, represents a significant new avenue for future revenue.
3. Leveraging Strategic Partnerships and Intellectual Property Expansion: SILO Pharma's collaborations with academic institutions like Columbia University and the University of Maryland, Baltimore, and industry partners such as Kymanox, Resyca BV, and WuXi AppTec, are crucial for accelerating drug development, reducing risks, and accessing external expertise and funding. These partnerships, coupled with the global expansion of intellectual property (e.g., patents granted for SPC-15 in the U.S., Australia, and Japan), strengthen the company's market position and competitive advantage, paving the way for future licensing deals and commercial success.
4. Utilization of Proprietary Drug Delivery Systems: The company's focus on innovative drug delivery methods, such as intranasal formulations for SPC-15 and time-release ketamine-loaded implants for SP-26, provides a competitive edge. These advanced delivery systems aim to improve therapeutic efficacy, enhance patient convenience, and overcome challenges like crossing the blood-brain barrier, which could lead to broader market adoption and drive revenue as products reach commercialization.

Share Repurchases

• Silo Pharma's board of directors authorized a share repurchase program of up to $1 million of the company's common stock on February 23, 2026.
• The program allows for purchases on the open market, through privately negotiated transactions, or other means.

Share Issuance

• On February 23, 2026, Silo Pharma issued 848,320 shares of common stock, valued at $250,000, to its investor relations consultant as a commitment fee.
• On October 1, 2025, the company closed a registered direct offering of 2,857,143 shares of common stock at $0.875 per share, raising approximately $2.5 million for working capital and general corporate purposes.
• On September 30, 2022, Silo Pharma completed an underwritten public offering of 1,150,000 shares of common stock at $5.00 per share, generating gross proceeds of $5.75 million, which were intended for product development, marketing, working capital, and general corporate purposes.

Inbound Investments

• Silo Pharma received approximately $2.5 million from a registered direct offering of common stock in October 2025.
• The company raised approximately $2 million through a public offering of common stock and warrants announced in May 2025.
• In September 2022, Silo Pharma secured gross proceeds of $5.75 million from a public offering of its common stock.

Outbound Investments

• As of October 23, 2025, Silo Pharma launched a digital assets treasury strategy, making initial cryptocurrency purchases in Bitcoin, Ethereum, Solana, and ResearchCoin.
• Initial purchases of Ethereum (ETH) and Solana (SOL) tokens were made by September 16, 2025, with the intention of staking them for revenue generation and capital appreciation.